Area of research
Surgery · Pulmonary and Respiratory Medicine
Research interest
Research interests include Bladder and Urothelial Cancer Treatments, Urinary and Genital Oncology Studies, Prostate Cancer Diagnosis and Treatment, and Renal cell carcinoma treatment.
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancer
Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte–Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin–Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer
Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin‒Unresponsive Nonmuscle-Invasive Bladder Cancer
N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review
IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non–Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013
Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC).
Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial
Natural History of Multiple Recurrences in Intermediate-Risk Non-Muscle Invasive Bladder Cancer: Lessons From a Prospective Cohort
The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-Analysis
Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients.
Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial
“Real-world” outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma
SIU–ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer
Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients
An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results
Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma
The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era
Population-based assessment of racial/ethnic differences in utilization of radical cystectomy for patients diagnosed with bladder cancer
Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008
Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma
Immunotherapy for the Treatment of Urothelial Carcinoma
Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer
Comparative Effectiveness of Robot-assisted Versus Open Radical Prostatectomy Cancer Control
Measuring the cost of care in benign prostatic hyperplasia using time-driven activity-based costing (TDABC)
The Role of Magnetic Resonance Imaging in Delineating Clinically Significant Prostate Cancer
Recurrence of high‐risk bladder cancer: A population‐based analysis
ARISER: A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC—Results and implications for adjuvant clinical trials.
Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma